MediTrial s.r.o.

At MediTrial s.r.o. the pulmonary department focuses on advancing treatments for severe eosinophilic asthma and chronic obstructive pulmonary disease (COPD). Current studies aim to test new biologic and small‑molecule therapies that can lower the frequency of severe exacerbations and improve long‑term disease control.

• Severe eosinophilic asthma
• Chronic obstructive pulmonary disease (COPD)
• Evaluation of novel anti‑inflammatory agents

Recent trials are evaluating the efficacy of dexpramipexole in reducing asthma attacks and the long‑term safety of tozorakimab as an add‑on therapy for COPD patients who have stopped smoking.